How did ETON's Q4 earnings surprise impact its annual performance?

Eton Pharmaceuticals' (ETON) Q4 earnings surprise had a significant impact on its annual performance, resulting in a negative net income for the year 2024. 1. **Q4 Earnings Surprise**: - Eton Pharmaceuticals experienced an EPS surprise of -$0.02 for Q4 2024. - This negative surprise indicates that the company's actual performance for the quarter was below market expectations. |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |ETON|ETON.O|Eton Pharmaceuticals|2024 Q1|69.51127819548873|-811000|185| |ETON|ETON.O|Eton Pharmaceuticals|2024 Q2|-166.70322439131388|-3041000|185| |ETON|ETON.O|Eton Pharmaceuticals|2024 Q3|208.29015544041448|627000|185| |ETON|ETON.O|Eton Pharmaceuticals|2024 Q4|73.49290780141844|-598000|185| 2. **Annual Net Income**: - Despite the Q4 earnings surprise, the company's annual net income for 2024 was -$3.82 million. - This substantial loss for the year suggests that the Q4 performance was part of a broader trend of declining profitability. 3. **Impact on Annual Performance**: - The Q4 earnings surprise contributed to the negative annual net income, indicating that the company faced significant challenges in that quarter. - The combined effect of the Q4 performance and the previous quarters likely led to the substantial annual loss. 4. **Conclusion**: - Eton Pharmaceuticals' Q4 earnings surprise had a detrimental effect on its annual performance, resulting in a significant financial loss for the year 2024. - The company's management will need to address the underlying issues that led to this performance in order to improve future results.